Compare Merck & Co., Inc. (MRK) vs ServiceNow Inc (NOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs ServiceNow Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while ServiceNow Inc trades at $131.51 (market cap $138.75B). The key difference: Merck & Co., Inc. is far larger — about 2.6× ServiceNow Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while ServiceNow Inc pays none. Which is the better fit depends on your goals.
| MRK | NOW | |
|---|---|---|
Market Cap | $366.28B | $138.75B |
Sector | Health | Technology |
52-Week High | $156.43 | $192.23 |
52-Week Low | $77.60 | $83.00 |
Enterprise Value | $413.04B | $142.54B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
ServiceNow (NOW) trades at $131.11, down 7.19% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew from $7.2B in 2022 to $13.28B in 2025, though net income margin has fluctuated. Positive sentiment is driven by AI integration and conference presentations, while high valuation ratios like a P/E of 83.88 present risks.
The outlook remains positive due to robust revenue growth and AI-driven business expansion, but elevated valuations and competitive pressures warrant caution. Analyst consensus is strongly bullish with a $141.46 price target, though investors should monitor execution risks and macroeconomic headwinds that could impact future performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About ServiceNow Inc
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management (ITSM), expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service (PaaS).
Read more on NOW →
